Production (Stage)
Akari Therapeutics, Plc
AKTX
$1.13
-$0.0143-1.25%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 33.44% | 8.84% | -0.84% | -88.95% | -656.04% |
| Total Depreciation and Amortization | -- | 0.00% | -100.00% | -100.00% | 1,200.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,210.11% | 122.37% | -89.13% | 290.65% | 98.33% |
| Change in Net Operating Assets | -64.52% | 699.48% | 1,203.28% | 648.66% | 383.84% |
| Cash from Operations | 46.83% | 51.83% | 39.16% | -4.26% | 17.13% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -200.00% | 2,800.00% | -- | -- |
| Total Debt Repaid | -139.07% | -- | -- | -- | -- |
| Issuance of Common Stock | 53.09% | -11.03% | -- | 2,337.80% | -46.17% |
| Repurchase of Common Stock | -- | -- | -13,500.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 40.89% | -38.75% | -- | 2,567.70% | -52.86% |
| Foreign Exchange rate Adjustments | -- | -83.33% | 300.00% | -200.00% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 99.33% | 146.61% | 21.18% | 165.14% | -51.98% |